ArticlePain and therapy2026
Comparative Cost-Utility and Clinical Efficacy of 5-HT3 Receptor Antagonists in Sufentanil-Based PCIA: A Propensity Score-Matched Analysis.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionPostoperative pain management using sufentanil-based patient-controlled intravenous analgesia (PCIA) is often compromised by opioid-induced nausea and vomiting. Although 5-HT3 receptor antagonists are commonly added to PCIA regimens, the effectiveness of continuous of low-concentration infusion strategies remains uncertain from a pharmacokinetic perspective. Furthermore, China's national volume-based procurement (VBP) policy has drastically altered the cost landscape, necessitating a re-evaluation of premium agents such as palonosetron. This study aimed to assess the incremental clinical outcomes and cost-effectiveness of palonosetron versus ondansetron in this specific post-VBP setting.
methodsWe conducted a retrospective cohort study with propensity score matching (PSM). Patients receiving sufentanil-based PCIA were grouped as sufentanil alone, sufentanil plus ondansetron, or sufentanil plus palonosetron. The primary outcomes were the incidence of postoperative nausea and vomiting (PONV). A cost-effectiveness analysis (CEA) was performed using bootstrapping and cost-effectiveness acceptability curves (CEAC).
resultsAfter matching, neither palonosetron nor ondansetron significantly reduced overall PONV incidence compared with sufentanil alone. However, subgroup analyses revealed that palonosetron significantly reduced severe nausea in elderly patients (P < 0.05). From an economic perspective, palonosetron demonstrated a high probability (87.0%) of being cost-saving in a probabilistic sensitivity analysis, whereas ondansetron was likely to be "dominated."
conclusionsUnder low-concentration background infusion regimens, 5-HT3 antagonists may provide limited benefit in the general patient population, especially high-risk female patients. However, in the context of VBP-driven price reductions, palonosetron may represent a cost-saving option, with potential benefits in elderly patients, and may confer additional prophylactic advantages in male patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.